<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair:</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td>Surgeon's perspective: Imaging and treating primary prostate cancer</td>
<td>Hossein Jadvar (USA) &amp; Michael Hofman (AUS)</td>
<td>A/Prof. Declan Murphy, Peter MacCallum Cancer Centre, Melbourne, Australia</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>PET/CT and PET/MRI in Prostate and Urological Malignancy</td>
<td></td>
<td>Dr. Louise Emmett, St Vincent’s Hospital, Sydney, Australia</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>The Power of Precision Oncology: Improved Overall Survival after 5 Years of PSMA Radioligand Therapy in &gt;200 Prostate Cancer Patients</td>
<td>Richard Baum (DEU) &amp; David Pattison (AUS)</td>
<td>Prof. Richard Baum, Zentralklinik, Bad Berka, Germany</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>A Clinical Overview of Neuroendocrine Tumours</td>
<td></td>
<td>Dr. David Chan, Royal North Shore Hospital, Sydney, Australia</td>
</tr>
<tr>
<td>16:45-17:15</td>
<td>The Role of PET imaging in Neuroendocrine Tumours</td>
<td></td>
<td>Dr. Grace Kong, Peter MacCallum Cancer Centre, Melbourne, Australia</td>
</tr>
<tr>
<td>17:15-17:45</td>
<td>Theranostics of Neuroendocrine Neoplasms – past, present and future of PRRT</td>
<td></td>
<td>Dr. Aviral Singh, Zentralklinik, Bad Berka, Germany</td>
</tr>
</tbody>
</table>
1615 – 1745 ONCOLOGY 3: GYNAECOLOGICAL CARCINOMA

Chair: Wim Oyen (GBR) & Michael McKay (AUS)

16:15 – 16:45
**Gynaecological cancers: value of PET/MR and non-FDG tracers**

**Learning objectives:**
1. To understand how PET/MR may add value in gynaecological cancers
2. To learn how non-FDG tracers may be of value in gynaecological cancers

Prof. Andreas Kjaer, University of Copenhagen, Denmark

30 mins

16:45 – 17:15
**PET/CT and PET/MRI in Gynaecological Carcinoma**

At the conclusion of this CME activity, the learner should be better able to:
1. Understand the role of FDG PET/CT for staging of cervix cancer and ovarian cancer and why it is a clinically valuable supplement for the FIGO classification
2. Understand the usefulness of FDG PET/CT in planning of radiotherapy for treatment of cervix cancer and for deciding the treatment for ovarian cancer.
3. Acknowledge the drawbacks of FDG PET/CT in oncology
4. Discuss the possible applications for PET/MRI in gynaecological carcinoma

Dr. Annika Loft, Dept of Clin Phys, Nucl Med & PET, Copenhagen, Denmark

30 mins

17:15 – 17:45
**Sentinel Lymphoscintigraphy in Gynaecological Carcinoma**

**Learning Objectives:**
1. Analyse the current situation (guidelines)
2. Illustrate the methods employed
3. Explore the future directions

Dr. Francesco Giammarile, IAEA, Vienna, Austria

30 mins
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Speakers</th>
<th>Duration</th>
</tr>
</thead>
</table>
| 10:30-12:00 | ONCOLOGY 4: HEAD & NECK CARCINOMA | John Koutsikos (GRC) & Paul Thomas (AUS) | **Overview:** An oncologist approach to the Management of Head and Neck Cancer  
Learning objectives:  
1. To provide an overview of best practice in the clinical management of head and neck cancer patients  
2. To discuss current controversies in the management of head and neck cancer patients  
3. To discuss the roles of nuclear medicine in the standard management and also in areas of controversies  
A/Prof. Hui Gan, Austin Health & Olivia Newton-John Cancer Research Institute, Melbourne, Australia | 30 mins   |
| 11:00-11:30 | Read with the Experts: SPECT/CT lymphoscintigraphy & PET/CT in Head & Neck Cancer |  
**Learning Objectives:**  
1. To review common head and neck cancers with PET/CT  
2. To review the head and neck lymphoscintigraphy with SPECT/CT  
Prof. Rathan Subramaniam, University Texas South Western, USA | 30 mins   |
| 11:30-12:00 | The contribution of molecular imaging to radiotherapy planning and response evaluation in head and neck cancer |  
**Learning Objectives:**  
1. To understand how PET/CT can be incorporated in treatment planning in head & neck cancer patients  
2. To Review technical aspects of acquiring PET/CT for use in radiotherapy treatment planning  
3. To review the role of molecular imaging in evaluating response to radiotherapy in head & neck cancer patients  
Dr. Michael McKay, Austin Health & La Trobe University, Melbourne, Australia | 30 mins   |
| 14:00-15:30 | ONCOLOGY 5: NEURO-ONCOLOGY | Andreas Fotopoulos (GRC) & Geoff Schrembri (AUS) | **Current practice and controversies in Neuro-Oncology**  
Learning objectives:  
1. To provide an overview of best practice in the clinical management of neuro-oncology patients  
2. To discuss current controversies in the management of neuro-oncology patients  
3. To discuss the roles of nuclear medicine in the standard management and also in areas of controversies  
A/Prof. Hui Gan, Austin Health & Olivia Newton-John Cancer Research Institute, Melbourne, Australia | 30 mins   |
| 14:30-15:00 | Read with the Experts: PET in Neuro-Oncology |  
**Learning Objectives:**  
1. To discuss the potential and the challenges of imaging in Neuro-Oncology  
2. To provide an overview of PET tracers in Neuro-Oncology, with a focus on amino acid PET imaging  
3. To identify areas of future research and development  
A/Prof. Roslyn Francis, University of Western Australia, Perth Australia | 30 mins   |
| 15:00-15:30 | Neuro-oncology: Treat With The Experts |  
**Learning Objectives:**  
1. The principle of Boron Neutron Capture Therapy (BNCT)  
2. How to deliver boron-10 specifically to cancer  
3. The role of PET-CT in BNCT  
Prof. Jun Hatazawa, Osaka University Graduate School of Medicine, Osaka, Japan | 30 mins   |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair/Institution</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>Overview of Lymphoma from a Clinician’s Perspective</td>
<td>Prof. John Seymour, Peter MacCallum Cancer Centre, Melbourne, Australia</td>
<td>30 mins</td>
</tr>
<tr>
<td>11:00</td>
<td>FDG-PET/CT for assessment of treatment response in lymphoma</td>
<td>Prof. Wim J.G. Oyen, The Institute of Cancer Research, Sutton, UK</td>
<td>30 mins</td>
</tr>
<tr>
<td>11:30</td>
<td>Radioimmunotherapy of Lymphoma: Past, Present and Future</td>
<td>Prof. Richard L. Wahl, Washington University in St Louis School of Medicine, USA</td>
<td>30 mins</td>
</tr>
<tr>
<td>14:00</td>
<td>Management of NSCLC in the age of immunotherapy</td>
<td>A/Prof. Tom John, Austin Health &amp; Olivia Newton-John Cancer Research Institute, Melbourne, Australia</td>
<td>30 mins</td>
</tr>
<tr>
<td>14:30</td>
<td>FDG PET/CT in Lung Cancer</td>
<td>A/Prof. Eddie Lau, Austin Health, Melbourne, Australia</td>
<td>30 mins</td>
</tr>
<tr>
<td>15:00</td>
<td>Role of PET/CT in curative-intent treatment of lung cancer with radiotherapy</td>
<td>Prof. Michael MacManus, Peter MacCallum Cancer Centre, Melbourne, Australia</td>
<td>30 mins</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Chair/ Speaker, Location, USA</td>
<td>Duration</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------</td>
<td>---------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>Molecular Imaging for Oncology Drug Development</td>
<td>Prof. Steven Larson, Memorial Sloan Kettering Cancer Centre, New York, USA</td>
<td>30 mins</td>
</tr>
<tr>
<td>16:45-17:15</td>
<td>Creating Probes for Theranostics</td>
<td>A/Prof. Andrei Iagaru, Stanford University Medical Centre, USA</td>
<td>30 mins</td>
</tr>
<tr>
<td>17:15-17:45</td>
<td>Theranostics Overview of Prostate Carcinoma</td>
<td>A/Prof. Hossein Jadvar, University of Southern California, Los Angeles USA</td>
<td>30 mins</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Chair</td>
<td>Learning Objectives</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 10:30-12:00 | ONCOLOGY 9: COLORECTAL CARCINOMA | Chair: Partha Choudary (IND) & Eva Wegner (AUS) | Overview of Colorectal Carcinoma from a Clinician’s Perspective  
1. To provide an overview of best practice in the clinical management of colorectal cancer patients  
2. To discuss current controversies in the management of colorectal cancer patients  
3. To discuss the roles of nuclear medicine in the standard management and also in areas of controversies in colorectal cancer | Prof. Alexander Heriot, Peter MacCallum Cancer Centre, Melbourne, Australia |
| 11:00-11:30 | Read with the Experts: Hepatic metastases in colorectal cancer | Chair: Kristoff Muylle (BEL) & Sze Ting Lee (AUS) | Read with the Experts: Hepatic metastases in colorectal cancer  
1. Understand the role of multimodality imaging in work-up of locoregional therapy of colorectal cancer liver metastasis  
2. Understand the use of FDG PET/CT for evaluating chemosensitivity of colorectal cancer liver metastases  
3. Opportunity and limits of the use of MAA SPECT-CT for pre-SIRT dosimetry and response prediction | Prof. Patrick Flamen, Jules Bourdet Institute, Brussels, Belgium |
| 11:30-12:00 | Treat with the Experts: Regional treatment with 90Y-SIRsphere | | Treat with the Experts: Regional treatment with 90Y-SIRsphere  
1. To understand the concept of radioembolization with SIRT  
2. To understand how regional treatment with 90Y-SIRsphere is utilized in colorectal cancer patients  
3. To review technical aspects of regional treatment with 90Y-SIRsphere | Dr. Elizabeth Bernard, Royal North Shore Hospital, Sydney, Australia |
| 14:00-15:30 | ONCOLOGY 10: BREAST CARCINOMA | Chair: Kristoff Muylle (BEL) & Sze Ting Lee (AUS) | Overview of Breast Cancer from a Clinician’s Perspective  
1. To provide an overview of best practice in the clinical management of breast cancer patients  
2. To discuss implications of staging and management of breast cancer  
3. To discuss the roles of nuclear medicine in the standard management of breast cancer | Prof. Shereen Loi, Peter MacCallum Cancer Centre, Melbourne, Australia |
| 14:30-15:00 | Read with the Experts: PET/CT in Breast Carcinoma | | Read with the Experts: PET/CT in Breast Carcinoma  
1. To describe normal patterns, pearls and pitfalls in interpretation of PET/CT in breast cancer  
2. To discuss the clinical diagnostic utility of PET/CT imaging in breast cancer  
3. The role of PET imaging in theranostics/treatment planning | Prof. Enrique Estrada Lobato, IAEA, Vienna, Austria |
| 16:15-17:45 | ONCOLOGY 11: HEPATOBILARY & GASTRIC CARCINOMA | Chair: John Buscombe (GBR) & Gabriella Cehic (AUS) | Clinical utility of FDG-PET/CT in gastric cancer  
1. To review the characteristics of gastric cancer  
2. To learn clinical utility and limitation of FDG-PET in diagnostic imaging of gastric cancer | Dr. Yuji Nakamoto, Kyoto University, Japan |
| 16:45-17:15 | C-11 acetate and F-18 FDG PET/CT for hepatocellular carcinoma (HCC) research | | C-11 acetate and F-18 FDG PET/CT for hepatocellular carcinoma (HCC) research  
1. Prognostic value of F-18 FDG PET/CT in HCC patients: the results of KSNM (Korean society of nuclear medicine) CTN (clinical trials network) research  
2. Difference in diagnostic accuracy between C-11 acetate and F-18 FDG PET/CT through understanding of tumour microenvironment | Dr. Seong Yeong Kwon, Chonnam National University Hwasun Hospital, Jeonnam, Korea |
| 17:15-17:45 | Role of MRI in the Treatment of Hepatocellular & Gastric Cancer with radiotherapy | | Role of MRI in the Treatment of Hepatocellular & Gastric Cancer with radiotherapy  
1. Central role of PET/MRI in selecting patients for curative intent radiotherapy/chemoradiotherapy  
2. How to use PET/MRI for target volume definition | Dr. Mark Goodwin, Austin Health, Melbourne, Australia |